文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Novavax 的 NVX-COV2373 可引发对奥密克戎亚谱系的中和作用。

Novavax NVX-COV2373 triggers neutralization of Omicron sub-lineages.

机构信息

National Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa.

MRC Antibody Immunity Research Unit, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.

出版信息

Sci Rep. 2023 Jan 21;13(1):1222. doi: 10.1038/s41598-023-27698-x.

DOI:10.1038/s41598-023-27698-x
PMID:36681693
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9867547/
Abstract

The SARS-CoV-2 Omicron (B.1.1.529) Variant of Concern (VOC) and its sub-lineages (including BA.2, BA.4, BA.5, BA.2.12.1) contain spike mutations that confer high level resistance to neutralizing antibodies induced by vaccination with ancestral spike or infection with previously circulating variants. The NVX-CoV2373 vaccine, a protein nanoparticle vaccine containing the ancestral spike sequence, has value in countries with constrained cold-chain requirements. Here we report neutralizing titers following two or three doses of NVX-CoV2373. We show that after two doses, Omicron sub-lineages BA.1 and BA.4/BA.5 were resistant to neutralization by 72% (21/29) and 59% (17/29) of samples respectively. However, after a third dose of NVX-CoV2373, we observed high titers against Omicron BA.1 (GMT: 1,197) and BA.4/BA.5 (GMT: 582), with responses similar in magnitude to those triggered by three doses of an mRNA vaccine. These data are of particular relevance as BA.4/BA.5 is dominating in multiple locations, and highlight the potential utility of the NVX-CoV2373 vaccine as a booster in resource-limited environments.

摘要

SARS-CoV-2 的奥密克戎（B.1.1.529）变体和其亚谱系（包括 BA.2、BA.4、BA.5、BA.2.12.1）含有刺突突变，这些突变使疫苗接种或先前流行变体感染诱导的中和抗体的水平产生高度抗性。NVX-CoV2373 疫苗是一种含有原始刺突序列的蛋白纳米颗粒疫苗，在冷链要求有限的国家具有价值。在此，我们报告了接种两剂或三剂 NVX-CoV2373 后的中和效价。我们发现，接种两剂后，奥密克戎亚谱系 BA.1 和 BA.4/BA.5 分别对 72%（21/29）和 59%（17/29）的样本具有抗中和作用。然而，接种第三剂 NVX-CoV2373 后，我们观察到针对奥密克戎 BA.1（GMT：1197）和 BA.4/BA.5 的高滴度（GMT：582），其反应强度与三剂 mRNA 疫苗相似。这些数据在 BA.4/BA.5 在多个地区占主导地位的情况下具有特别重要的意义，突显了 NVX-CoV2373 疫苗作为资源有限环境中加强针的潜在效用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0336/9867754/a6aa2a4919a8/41598_2023_27698_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0336/9867754/f1dfacab4f24/41598_2023_27698_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0336/9867754/a6aa2a4919a8/41598_2023_27698_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0336/9867754/f1dfacab4f24/41598_2023_27698_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0336/9867754/a6aa2a4919a8/41598_2023_27698_Fig2_HTML.jpg

相似文献

[1]
Novavax NVX-COV2373 triggers neutralization of Omicron sub-lineages.

Sci Rep. 2023-1-21

[2]
Immunogenicity and Safety of Heterologous Omicron BA.1 and Bivalent SARS-CoV-2 Recombinant Spike Protein Booster Vaccines: A Phase 3 Randomized Clinical Trial.

J Infect Dis. 2024-7-25

[3]
Immunogenicity and safety of a fourth homologous dose of NVX-CoV2373.

Vaccine. 2023-6-29

[4]
Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial.

Lancet Infect Dis. 2022-11

[5]
NVX-CoV2373-induced cellular and humoral immunity towards parental SARS-CoV-2 and VOCs compared to BNT162b2 and mRNA-1273-regimens.

J Clin Virol. 2022-12

[6]
Immunogenicity and safety of heterologous booster with protein-based COVID-19 vaccine (NVX-CoV2373) in healthy adults: A comparative analysis with mRNA vaccines.

J Formos Med Assoc. 2024-3

[7]
Efficacy of mRNA-1273 and Novavax ancestral or BA.1 spike booster vaccines against SARS-CoV-2 BA.5 infection in nonhuman primates.

Sci Immunol. 2023-10-27

[8]
A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Novavax COVID-19 Vaccine (NVX-CoV2373), a recombinant spike protein vaccine with Matrix-M adjuvant to prevent disease caused by SARS-CoV-2 viruses.

Vaccine. 2023-10-26

[9]
Immunogenicity and safety of NVX-CoV2373 as a booster: A phase 3 randomized clinical trial in adults.

Vaccine. 2023-9-22

[10]
Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial.

Lancet HIV. 2022-5

引用本文的文献

[1]
Adaptation of the Vaccine Prophylaxis Strategy to Variants of the SARS-CoV-2 Virus.

Vaccines (Basel). 2025-7-17

[2]
T-cell responses induced by SARS-CoV-2 index-virus nanoparticle protein vaccine to the ancestral and omicron variants 6 months following primary vaccination.

Commun Med (Lond). 2025-6-10

[3]
Safety and immunogenicity of four sequential doses of NVX-CoV2373 in adults and adolescents: A phase 3, randomized, placebo-controlled trial (PREVENT-19).

Vaccine. 2025-6-5

[4]
Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine with Matrix-M adjuvant (NVX-CoV2373) versus a primary series in people living with and without HIV-1 infection in South Africa: A randomized crossover phase 2a/2b trial.

Hum Vaccin Immunother. 2024-12-31

[5]
Hybrid Immunity against SARS-CoV-2 Variants: A Narrative Review of the Literature.

Vaccines (Basel). 2024-9-14

[6]
Vaccination and Therapeutics.

Adv Exp Med Biol. 2024

[7]
Immunogenicity and efficacy of XBB.1.5 rS vaccine against the EG.5.1 variant of SARS-CoV-2 in Syrian hamsters.

J Virol. 2024-10-22

[8]
Validation of a Pseudovirus Neutralization Assay for Severe Acute Respiratory Syndrome Coronavirus 2: A High-Throughput Method for the Evaluation of Vaccine Immunogenicity.

Microorganisms. 2024-6-14

[9]
A Narrative Overview of Coronavirus Infection: Clinical Signs and Symptoms, Viral Entry and Replication, Treatment Modalities, and Management.

Curr Top Med Chem. 2024

[10]
COVID-19 Variants and Vaccine Development.

Viruses. 2024-5-10

本文引用的文献

[1]
Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial.

Lancet Infect Dis. 2022-11

[2]
Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines.

Science. 2022-8-19

[3]
Humoral and cellular immune memory to four COVID-19 vaccines.

Cell. 2022-7-7

[4]
Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa.

Nat Med. 2022-9

[5]
BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection.

Nature. 2022-8

[6]
SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated, individuals.

Cell Host Microbe. 2022-6-8

[7]
Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa.

Nature. 2022-3

[8]
WHO lists 9th COVID-19 vaccine for emergency use with aim to increase access to vaccination in lower-income countries.

Saudi Med J. 2022-1

[9]
Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization.

Nature. 2022-2

[10]
mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant.

Cell. 2022-2-3

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索